Resection of hepatitis B virus-related hepatocellular carcinoma: Evolving strategies and emerging therapies to improve outcome

World Journal of Gastroenterology

Volumn 20, Issue 35, 2014, Pages 12473-12484

  Chau, Gar Yang ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Adjuvant therapy; Hepatic resection; Hepatitis B virus; Hepatocellular carcinoma; Outcome

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT;

ARTICLE; CANCER RECURRENCE; CANCER STAGING; CHEMOEMBOLIZATION; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER LOBECTOMY; LIVER RESECTION; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PREOPERATIVE EVALUATION; RECURRENCE RISK; SURGICAL MORTALITY; VEIN BLOOD FLOW; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; CARCINOMA, HEPATOCELLULAR; COMPLICATION; HEPATITIS B, CHRONIC; LIVER NEOPLASMS; MINIMAL RESIDUAL DISEASE; MORTALITY; PATHOLOGY; PROCEDURES; SECONDARY; TREATMENT OUTCOME; TUMOR RECURRENCE; VIROLOGY;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; HEPATECTOMY; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; TREATMENT OUTCOME;

EID: 84909606702     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i35.12473     Document Type: Article

References (97)

1. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16 [PMID: 15508102 DOI: 10.1053/j.gastro.2004.09.011]
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917 [PMID: 14667750 DOI: 10.1016/ S0140-6736(03)14964-1]
3. But DY, Lai CL, Yuen MF. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol 2008; 14: 1652-1656 [PMID: 18350595 DOI: 10.3748/wjg.14.1652]
4. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335-352 [PMID: 18096267 DOI: 10.1016/j.jhep.2007.11.011]
5. Lim SG , Mohammed R, Yuen MF, Kao JH. Prevention of hepatocellular carcinoma in hepatitis B virus infection. J Gastroenterol Hepatol 2009; 24: 1352-1357 [PMID: 19702903 DOI: 10.1111/j.1440-1746.2009.05985.x]
6. Pollicino T, Saitta C, Raimondo G. Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogenesis 2011; 32: 1122-1132 [PMID: 21665892 DOI: 10.1093/carcin/bgr108]
7. Pawlik TM , Poon RT, Abdalla EK, Ikai I, Nagorney DM, Belghiti J, Kianmanesh R, Ng IO, Curley SA, Yamaoka Y, Lauwers GY, Vauthey JN. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery 2005; 137: 403-410 [PMID: 15800485 DOI: 10.1016/j.surg.2004.12.012]
8. Andreou A, Vauthey JN, Cherqui D, Zimmitti G, Ribero D, Truty MJ, Wei SH, Curley SA, Laurent A, Poon RT, Belghiti J, Nagorney DM, Aloia TA. Improved long-term survival after major resection for hepatocellular carcinoma: a multicenter analysis based on a new definition of major hepatectomy. J Gastrointest Surg 2013; 17: 66-77; discussion 77 [PMID: 22948836 DOI: 10.1007/s11605-012-2005-4]
9. Chau GY, Lui WY, King KL, Wu CW. Evaluation of effect of hemihepatic vascular occlusion and the Pringle maneuver during hepatic resection for patients with hepatocellular carcinoma and impaired liver function. World J Surg 2005; 29: 1374-1383 [PMID: 16240064 DOI: 10.1007/s00268-005-7766-4]
10. Hsu KY, Chau GY, Lui WY, Tsay SH, King KL, Wu CW. Predicting morbidity and mortality after hepatic resection in patients with hepatocellular carcinoma: the role of Model for End-Stage Liver Disease score. World J Surg 2009; 33: 2412-2419 [PMID: 19756859 DOI: 10.1007/s00268-009-0202-4]
11. Dahiya D, Wu TJ, Lee CF, Chan KM, Lee WC, Chen MF. Minor versus major hepatic resection for small hepatocellular carcinoma (HCC) in cirrhotic patients: a 20-year experience. Surgery 2010; 147: 676-685 [PMID: 20004441 DOI: 10.1016/j.surg.2009.10.043]
12. Torzilli G, Makuuchi M, Inoue K, Takayama T, Sakamoto Y, Sugawara Y, Kubota K, Zucchi A. No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach. Arch Surg 1999; 134: 984-992 [PMID: 10487594 DOI: 10.1001/archsurg.134.9.984]
13. Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 1999; 229: 322-330 [PMID: 10077043 DOI: 10.1097/00000658-199903000-00004]
14. Lei HJ, Chau GY, Lui WY, Tsay SH, King KL, Loong CC, Wu CW. Prognostic value and clinical relevance of the 6th Edition 2002 American Joint Committee on Cancer staging system in patients with resectable hepatocellular carcinoma. J Am Coll Surg 2006; 203: 426-435 [PMID: 17000385 DOI: 10.1016/j.jamc ollsurg.2006.06.030]
15. Chang CH, Chau GY, Lui WY, Tsay SH, King KL, Wu CW. Long-term results of hepatic resection for hepatocellular carcinoma originating from the noncirrhotic liver. Arch Surg 2004; 139: 320-335; discussion 326 [PMID: 15006892 DOI: 10.1001/archsurg.139.3.320]
16. Fan ST, Mau Lo C, Poon RT, Yeung C, Leung Liu C, Yuen WK, Ming Lam C, Ng KK, Ching Chan S. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg 2011; 253: 745-758 [PMID: 21475015 DOI: 10.1097/SLA.0b013e3182111195]
17. Chen WT, Chau GY, Lui WY, Tsay SH, King KL, Loong CC, Wu CW. Recurrent hepatocellular carcinoma after hepatic resection: prognostic factors and long-term outcome. Eur J Surg Oncol 2004; 30: 414-420 [PMID: 15063895 DOI: 10.1016/j.ejso.2004.01.013]
18. Ercolani G, Grazi GL, Ravaioli M, Del Gaudio M, Gardini A, Cescon M, Varotti G, Cetta F, Cavallari A. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg 2003; 237: 536-543 [PMID: 12677151 DOI: 10.1097/01.SLA.0000059988.22416.F2]
19. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236 [PMID: 16250051 DOI: 10.1002/hep.20933]
20. Lok AS. Hepatitis B: liver fibrosis and hepatocellular carcinoma. Gastroenterol Clin Biol 2009; 33: 911-915 [PMID: 19577871 DOI: 10.1016/j.gcb.2009.06.001]
21. Cescon M, Cucchetti A, Grazi GL, Ferrero A, Viganò L, Ercolani G, Ravaioli M, Zanello M, Andreone P, Capussotti L, Pinna AD. Role of hepatitis B virus infection in the prognosis after hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a Western dual-center experience. Arch Surg 2009; 144: 906-913 [PMID: 19841357 DOI: 10.1001/archsurg.2009.99]
22. Chen CH, Huang GT, Yang PM, Chen PJ, Lai MY, Chen DS, Wang JD, Sheu JC. Hepatitis B- and C-related hepatocellular carcinomas yield different clinical features and prognosis. Eur J Cancer 2006; 42: 2524-2529 [PMID: 16920352 DOI: 10.1016/j.ejca.2006.06.007]
23. Hu Z, Zhou J, Wang H, Zhang M, Li S, Huang Y, Wu J, Li Z, Zhou L, Zheng S. Survival in liver transplant recipients with hepatitis B- or hepatitis C-associated hepatocellular carcinoma: the Chinese experience from 1999 to 2010. PLoS One 2013; 8: e61620 [PMID: 23613886 DOI: 10.1371/journal.pone.0061620]
24. Xuan SY , Xin YN, Chen H, Shi GJ, Guan HS, Li Y. Significance of hepatitis B virus surface antigen, hepatitis C virus expression in hepatocellular carcinoma and pericarcinomatous tissues. World J Gastroenterol 2007; 13: 1870-1874 [PMID: 17465484]
25. Messerini L, Novelli L, Comin CE. Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma. J Clin Pathol 2004; 57: 867-871 [PMID: 15280410 DOI: 10.1136/jcp.2003.015784]
26. Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G. Current management strategy of hepatocellular carcinoma. World J Gastroenterol 2009; 15: 3210-3216 [PMID: 19598295 DOI: 10.3748/wjg.15.3210]
27. Chang WT, Kao WY, Chau GY, Su CW, Lei HJ, Wu JC, Hsia CY, Lui WY, King KL, Lee SD. Hepatic resection can provide long-term survival of patients with non-early-stage hepatocellular carcinoma: extending the indication for resection? Surgery 2012; 152: 809-820 [PMID: 22766361 DOI: 10.1016/j.surg.2012.03.024]
28. Young AL, Malik HZ, Abu-Hilal M, Guthrie JA, Wyatt J, Prasad KR, Toogood GJ, Lodge JP. Large hepatocellular carcinoma: time to stop preoperative biopsy. J Am Coll Surg 2007; 205: 453-462 [PMID: 17765162 DOI: 10.1016/j.jamcollsurg.2007.04.033]
29. Vauthey JN, Dixon E, Abdalla EK, Helton WS, Pawlik TM, Taouli B, Brouquet A, Adams RB. Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford) 2010; 12: 289-299 [PMID: 20590901 DOI: 10.1111/j.1477-2574.2010.00181.x]
30. Ayyappan AP, Jhaveri KS. CT and MRI of hepatocellular carcinoma: an update. Expert Rev Anticancer Ther 2010; 10: 507-519 [PMID: 20397916 DOI: 10.1586/era.10.24]
31. Freeny PC, Grossholz M, Kaakaji K, Schmiedl UP. Significance of hyperattenuating and contrast-enhancing hepatic nodules detected in the cirrhotic liver during arterial phase helical CT in pre-liver transplant patients: radiologic-histopathologic correlation of explanted livers. Abdom Imaging 2003; 28: 333-346 [PMID: 12719903 DOI: 10.1007/s00261-002-0053-z]
32. Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D, Duca P. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006; 101: 513-523 [PMID: 16542288 DOI: 10.1111/j.1572-0241.2006.00467.x]
33. Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008; 247: 311-330 [PMID: 18430871 DOI: 10.1148/radiol.2472061331]
34. Yoo SH, Choi JY, Jang JW, Bae SH, Yoon SK, Kim DG, Yoo YK, Rha SE, Lee YJ, Jung ES. Gd-EOB-DTPA-enhanced MRI is better than MDCT in decision making of curative treatment for hepatocellular carcinoma. Ann Surg Oncol 2013; 20: 2893-2900 [PMID: 23649931 DOI: 10.1245/s10434-013-3001-y]
35. Battaglia V, Bozzi E, Zingoni G, Bartolozzi C, Pisa IT. Correlation between histologic diagnosis ad MR signal intensity after Gd-EOB-DTPA administration of nodules detected within cirrhotic explanted livers: retrospective analysis. Eur Radiol 2010; 20 Suppl 1: S25
36. Hammerstingl R, Huppertz A, Breuer J, Balzer T, Blakeborough A, Carter R, Fusté LC, Heinz-Peer G, Judmaier W, Laniado M, Manfredi RM, Mathieu DG, Müller D, Mortelè K, Reimer P, Reiser MF, Robinson PJ, Shamsi K, Strotzer M, Taupitz M, Tombach B, Valeri G, van Beers BE, Vogl TJ. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 2008; 18: 457-467 [PMID: 18058107 DOI: 10.1007/s00330-007-0716-9]
37. Chau GY, Lui WY, Wu CW. Spectrum and significance of microscopic vascular invasion in hepatocellular carcinoma. Surg Oncol Clin N Am 2003; 12: 25-34, viii [PMID: 12735127 DOI: 10.1016/S1055-3207(02)00077-7]
38. Lui WY, Chau GY, Loong CC, Tsay SH, Wu JC, King KL, Chiu JH, Lai CR, P'eng FK. Hepatic segmentectomy for curative resection of primary hepatocellular carcinoma. Arch Surg 1995; 130: 1090-1097 [PMID: 7575122 DOI: 10.1001/archsurg.1995.01430100068014]
39. Makuuchi M, Hasegawa H, Yamazaki S. Ultrasonically guided subsegmentectomy. Surg Gynecol Obstet 1985; 161: 346-350 [PMID: 2996162]
40. Regimbeau JM, Kianmanesh R, Farges O, Dondero F, Sauvanet A, Belghiti J. Extent of liver resection influences the outcome in patients with cirrhosis and small hepatocellular carcinoma. Surgery 2002; 131: 311-317 [PMID: 11894036 DOI: 10.1067/msy.2002.121892]
41. Hasegawa K, Kokudo N, Imamura H, Matsuyama Y, Aoki T, Minagawa M, Sano K, Sugawara Y, Takayama T, Makuuchi M. Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg 2005; 242: 252-259 [PMID: 16041216 DOI: 10.1097/01.sla.0000171307.37401.db]
42. Shindoh J, Hasegawa K, Inoue Y, Ishizawa T, Nagata R, Aoki T, Sakamoto Y, Sugawara Y, Makuuchi M, Kokudo N. Risk factors of post-operative recurrence and adequate surgical approach to improve long-term outcomes of hepatocellular carcinoma. HPB (Oxford) 2013; 15: 31-39 [PMID: 23216777 DOI: 10.1111/j.1477-2574.2012.00552.x]
43. Cucchetti A , Cescon M, Ercolani G, Bigonzi E, Torzilli G, Pinna AD. A comprehensive meta-regression analysis on outcome of anatomic resection versus nonanatomic resection for hepatocellular carcinoma. Ann Surg Oncol 2012; 19: 3697-3705 [PMID: 22722807 DOI: 10.1245/s10434-012-2450-z]
44. Lee CS, Sung JL, Hwang LY, Sheu JC, Chen DS, Lin TY, Beasley RP. Surgical treatment of 109 patients with symptomatic and asymptomatic hepatocellular carcinoma. Surgery 1986; 99: 481-490 [PMID: 3006272]
45. Chau GY, Lui WY, Tsay SH, King KL, Loong CC, Chiu JH, Wu CW, P'eng FK. Prognostic significance of surgical margin in hepatocellular carcinoma resection: an analysis of 165 Childs' A patients. J Surg Oncol 1997; 66: 122-126 [PMID: 9354168 DOI: 10.1002/(SICI)1096-9098(199710)66]
46. Shi M, Guo RP, Lin XJ, Zhang YQ, Chen MS, Zhang CQ, Lau WY, Li JQ. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg 2007; 245: 36-43 [PMID: 17197963 DOI: 10.1097/01.sla.0000231758.07868.71]
47. Chen MF, Hwang TL, Jeng LB, Wang CS, Jan YY, Chen SC. Postoperative recurrence of hepatocellular carcinoma. Two hundred five consecutive patients who underwent hepatic resection in 15 years. Arch Surg 1994; 129: 738-742 [PMID: 7517662 DOI: 10.1001/archsurg.1994.01420310070012]
48. Masutani S, Sasaki Y, Imaoka S, Iwamoto S, Ohashi I, Kameyama M, Kabuto T, Ishikawa O, Furukawa H, Koyama H. The prognostic significance of surgical margin in liver resection of patients with hepatocellular carcinoma. Arch Surg 1994; 129: 1025-1030 [PMID: 7944931 DOI: 10.1001/archsurg.1994.01420340039007]
49. Nara S, Shimada K, Sakamoto Y, Esaki M, Kishi Y, Kosuge T, Ojima H. Prognostic impact of marginal resection for patients with solitary hepatocellular carcinoma: evidence from 570 hepatectomies. Surgery 2012; 151: 526-536 [PMID: 22244181 DOI: 10.1016/j.surg.2011.12.002]
50. Matsui Y, Terakawa N, Satoi S, Kaibori M, Kitade H, Takai S, Kwon AH, Kamiyama Y. Postoperative outcomes in patients with hepatocellular carcinomas resected with exposure of the tumor surface: clinical role of the no-margin resection. Arch Surg 2007; 142: 596-602; discussion 603 [PMID: 17638795 DOI: 10.1001/archsurg.142.7.596]
51. Makuuchi M, Yamamoto J, Takayama T, Kosuge T, Gunvén P, Yamazaki S, Hasegawa H. Extrahepatic division of the right hepatic vein in hepatectomy. Hepatogastroenterology 1991; 38: 176-179 [PMID: 1649789]
52. Li CH, Chau GY, Lui WY, Tsay SH, King KL, Hsia CY, Wu CW. Risk factors associated with intra-operative major blood loss in patients with hepatocellular carcinoma who underwent hepatic resection. J Chin Med Assoc 2003; 66: 669-675 [PMID: 14768854]
53. Lai EC, Fan ST, Lo CM, Chu KM, Liu CL. Anterior approach for difficult major right hepatectomy. World J Surg 1996; 20: 314-317; discussion 318 [PMID: 8661837 DOI: 10.1007/s002689900050]
54. Ozawa K. Hepatic function and liver resection. J Gastroenterol Hepatol 1990; 5: 296-309 [PMID: 2103412 DOI: 10.1111/j.1440-1746.1990.tb01632.x]
55. Liu CL, Fan ST, Cheung ST, Lo CM, Ng IO, Wong J. Anterior approach versus conventional approach right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled study. Ann Surg 2006; 244: 194-203 [PMID: 16858181 DOI: 10.1097/01.sla.0000225095.18754.45]
56. Shah SA, Cleary SP, Wei AC, Yang I, Taylor BR, Hemming AW, Langer B, Grant DR, Greig PD, Gallinger S. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery 2007; 141: 330-339 [PMID: 17349844 DOI: 10.1016/j.surg.2006.06.028]
57. Wu CC, Cheng SB, Yeh DC, Wang J, P'eng FK. Second and third hepatectomies for recurrent hepatocellular carcinoma are justified. Br J Surg 2009; 96: 1049-1057 [PMID: 19672929 DOI: 10.1002/bjs.6690]
58. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699 [PMID: 8594428 DOI: 10.1056/NEJM199603143341104]
59. Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002; 8: 873-883 [PMID: 12360427 DOI: 10.1053/ jlts.2002.34923]
60. Majno PE, Sarasin FP, Mentha G, Hadengue A. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis. Hepatology 2000; 31: 899-906 [PMID: 10733546 DOI: 10.1053/he.2000.5763]
61. Del Gaudio M, Ercolani G, Ravaioli M, Cescon M, Lauro A, Vivarelli M, Zanello M, Cucchetti A, Vetrone G, Tuci F, Ramacciato G, Grazi GL, Pinna AD. Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of Bologna experience. Am J Transplant 2008; 8: 1177-1185 [PMID: 18444925 DOI: 10.1111/j.1600-6143.2008.02229.x]
62. Hu Z, Wang W, Li Z, Ye S, Zheng SS. Recipient outcomes of salvage liver transplantation versus primary liver transplantation: a systematic review and meta-analysis. Liver Transpl 2012; 18: 1316-1323 [PMID: 22847898 DOI: 10.1002/lt.23521]
63. Adam R, Azoulay D, Castaing D, Eshkenazy R, Pascal G, Hashizume K, Samuel D, Bismuth H. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg 2003; 238: 508-518; discussion 518-519 [PMID: 14530722 DOI: 10.1097/01.sla.0000090449.87109.44]
64. Margarit C, Escartín A, Castells L, Vargas V, Allende E, Bilbao I. Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation. Liver Transpl 2005; 11: 1242-1251 [PMID: 16184539 DOI: 10.1002/lt.20398]
65. Sala M, Fuster J, Llovet JM, Navasa M, Solé M, Varela M, Pons F, Rimola A, García-Valdecasas JC, Brú C, Bruix J. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl 2004; 10: 1294-1300 [PMID: 15376311 DOI: 10.1002/lt.20202]
66. Wu CC, Ho YZ, Ho WL, Wu TC, Liu TJ, P'eng FK. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg 1995; 82: 122-126 [PMID: 7881929 DOI: 10.1002/bjs.1800820141]
67. Izumi R, Shimizu K, Iyobe T, Ii T, Yagi M, Matsui O, Nonomura A, Miyazaki I. Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology 1994; 20: 295-301 [PMID: 8045490 DOI: 10.1002/hep.1840200205]
68. Hasegawa K, Takayama T, Ijichi M, Matsuyama Y, Imamura H, Sano K, Sugawara Y, Kokudo N, Makuuchi M. Uraciltegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology 2006; 44: 891-895 [PMID: 17006925 DOI: 10.1002/hep.21341]
69. Lai EC, Lo CM, Fan ST, Liu CL, Wong J. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg 1998; 133: 183-188 [PMID: 9484732 DOI: 10.1001/archsurg.133.2.183]
70. Lau WY, Lai EC, Leung TW, Yu SC. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Ann Surg 2008; 247: 43-48 [PMID: 18156922 DOI: 10.1097/SLA.0b013e3181571047]
71. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356: 802-807 [PMID: 11022927 DOI: 10.1016/ S0140-6736(00)02654-4]
72. Chau GY. Adjuvant therapy for patients with hepatocellular carcinoma undergoing hepatic resection. Formas J Surg 2009; 42: 133-138
73. Lau WY, Lai EC, Lau SH. The current role of neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int 2009; 8: 124-133 [PMID: 19357024]
74. Chau GY, Wu CW, Lui WY, Chang TJ, Kao HL, Wu LH, King KL, Loong CC, Hsia CY, Chi CW. Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg 2000; 231: 552-558 [PMID: 10749617 DOI: 10.1097/00000658-200004000-00015]
75. Vauthey JN, Klimstra D, Franceschi D, Tao Y, Fortner J, Blumgart L, Brennan M. Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Am J Surg 1995; 169: 28-34; discussion 34-35 [PMID: 7817995 DOI: 10.1016/S0002-9610(99)80106-8]
76. Tsai TJ, Chau GY, Lui WY, Tsay SH, King KL, Loong CC, Hsia CY, Wu CW. Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery 2000; 127: 603-608 [PMID: 10840353 DOI: 10.1067/msy.2000.105498]
77. Ikai I, Yamaoka Y, Yamamoto Y, Ozaki N, Sakai Y, Satoh S, Shinkura N, Yamamoto M. Surgical intervention for patients with stage IV-A hepatocellular carcinoma without lymph node metastasis: proposal as a standard therapy. Ann Surg 1998; 227: 433-439 [PMID: 9527067 DOI: 10.1097/00000658-199803000-00016]
78. Shi J, Lai EC, Li N, Guo WX, Xue J, Lau WY, Wu MC, Cheng SQ. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol 2010; 17: 2073-2080 [PMID: 20131013 DOI: 10.1245/s10434-010-0940-4]
79. Marsh JW, Dvorchik I, Subotin M, Balan V, Rakela J, Popechitelev EP, Subbotin V, Casavilla A, Carr BI, Fung JJ, Iwatsuki S. The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology 1997; 26: 444-450 [PMID: 9252157 DOI: 10.1002/hep.510260227]
80. Hung HH, Lei HJ, Chau GY, Su CW, Hsia CY, Kao WY, Lui WY, Wu WC, Lin HC, Wu JC. Milan criteria, multi-nodularity, and microvascular invasion predict the recurrence patterns of hepatocellular carcinoma after resection. J Gastrointest Surg 2013; 17: 702-711 [PMID: 23225107 DOI: 10.1007/s11605-012-2087-z]
81. Ho CM, Lee PH, Shau WY, Ho MC, Wu YM, Hu RH. Survival in patients with recurrent hepatocellular carcinoma after primary hepatectomy: comparative effectiveness of treatment modalities. Surgery 2012; 151: 700-709 [PMID: 22284764 DOI: 10.1016/j.surg.2011.12.015]
82. Chau GY, Lui WY, Tsay SH, Chao Y, King KL, Wu CW. Postresectional adjuvant intraportal chemotherapy in patients with hepatocellular carcinoma: a case-control study. Ann Surg Oncol 2006; 13: 1329-1337 [PMID: 16897271 DOI: 10.1245/s10434-006-9004-1]
83. Regimbeau JM, Abdalla EK, Vauthey JN, Lauwers GY, Durand F, Nagorney DM, Ikai I, Yamaoka Y, Belghiti J. Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: results of a multicenter study. J Surg Oncol 2004; 85: 36-41 [PMID: 14696085]
84. Chen XH, Zhang BH, Xin Y, Ren ZG, Fan J, Qiu SJ, Zhou J. Risk factors for residual tumor after resection of hepatocellular carcinoma. World J Gastroenterol 2011; 17: 1889-1894 [PMID: 21528064 DOI: 10.3748/wjg.v17.i14.1889]
85. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011; 140: 1410-1426 [PMID: 21406195 DOI: 10.1053/j.gastro.2011.03.006]
86. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]
87. Printz C. Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM). Cancer 2009; 115: 4646 [PMID: 19806596 DOI: 10.1002/cncr.24673]
88. Ferro V, Dredge K, Liu L, Hammond E, Bytheway I, Li C, Johnstone K, Karoli T, Davis K, Copeman E, Gautam A. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost 2007; 33: 557-568 [PMID: 17629854 DOI: 10.1055/s-2007-982088]
89. Liu CJ, Lee PH, Lin DY, Wu CC, Jeng LB, Lin PW, Mok KT, Lee WC, Yeh HZ, Ho MC, Yang SS, Lee CC, Yu MC, Hu RH, Peng CY, Lai KL, Chang SS, Chen PJ. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol 2009; 50: 958-968 [PMID: 19303160 DOI: 10.1016/j.jhep.2008.12.023]
90. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971-975 [PMID: 10051505 DOI: 10.1002/hep.510290312]
91. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531 [PMID: 15470215 DOI: 10.1056/NEJMoa033364]
92. Hung IF, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol 2008; 103: 1663-1673 [PMID: 18616655 DOI: 10.1111/j.1572-0241.2008.01872.x]
93. Wei Q, Xu X, Ling Q, Zhou B, Zheng SS. Perioperative antiviral therapy for chronic hepatitis B-related hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2013; 12: 251-255 [PMID: 23742769 DOI: 10.1016/S1499-3872(13)60041-7]
94. Wu JC, Huang YH, Chau GY, Su CW, Lai CR, Lee PC, Huo TI, Sheen IJ, Lee SD, Lui WY. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 2009; 51: 890-897 [PMID: 19747749 DOI: 10.1016/j.jhep.2009.07.009]
95. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73 [PMID: 16391218 DOI: 10.1001/jama.295.1.65]
96. Chan AC, Chok KS, Yuen WK, Chan SC, Poon RT, Lo CM, Fan ST. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg 2011; 146: 675-681 [PMID: 21690443 DOI: 10.1001/archsurg.2011.125]
97. Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, Lin JT. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 2012; 308: 1906-1914 [PMID: 23162861 DOI: 10.1001/2012.jama.11975]